Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Regulation of tumor angiogenesis and mesenchymal-endothelial transition by p38α through TGF-β and JNK signaling.

Batlle R, Andrés E, Gonzalez L, Llonch E, Igea A, Gutierrez-Prat N, Berenguer-Llergo A, Nebreda AR.

Nat Commun. 2019 Jul 11;10(1):3071. doi: 10.1038/s41467-019-10946-y.

2.

Myeloid p38α signaling promotes intestinal IGF-1 production and inflammation-associated tumorigenesis.

Youssif C, Cubillos-Rojas M, Comalada M, Llonch E, Perna C, Djouder N, Nebreda AR.

EMBO Mol Med. 2018 Jul;10(7). pii: e8403. doi: 10.15252/emmm.201708403.

3.

Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors.

Gupta J, Igea A, Papaioannou M, Lopez-Casas PP, Llonch E, Hidalgo M, Gorgoulis VG, Nebreda AR.

Oncotarget. 2015 Apr 20;6(11):8539-51.

4.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.

Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.

Supplemental Content

Loading ...
Support Center